ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 258

Efficacy and Safety of the Chinese Herbal Compound Hou-Lou-Xiao-Ling Dan in Patients with Osteoarthritis of the Knee: Results of a Phase II International Study

Marc C. Hochberg1, Lixing Lao2, Patricia Langenberg3, Harry H. S. Fong4, David Y-W. Lee5 and Brian Berman2, 1Department of Medicine, University of Maryland, Baltimore, MD, 2Center for Integrative Medicine, University of Maryland, Baltimore, MD, 3University of Maryland, Baltimore, MD, 4University of Illinois at Chicago, Chicago, IL, 5Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: clinical trials, complimentary and alternative therapy and osteoarthritis, Knee

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Traditional Chinese Medicine (TCM), which includes the use of herbal medicines, is widely used to treat osteoarthritis (OA) of the knee in Asian societies; furthermore, many persons with OA in the United States use TCM therapies. The scientific basis for the use of TCM in the treatment of OA, however, is relatively sparse. Huo-Luo-Xiao-Ling (HLXL) Dan is a Chinese herbal compound that is used for the treatment of arthritis and Bi syndrome in Asia and has been shown to have anti-inflammatory and immunomodulatory properties in preclinical models of rheumatoid arthritis. The primary objective of this study was to examine the efficacy and safety of a proprietary formulation of HLXL Dan in patients with osteoarthritis (OA) of the knee who continued to have symptoms despite receiving standard analgesic and/or anti-inflammatory treatment.

Methods: A randomized, double-blind, placebo-controlled phase II clinical trial was conducted at two sites: the University of Maryland Center for Integrative Medicine and the Chinese University of Hong Kong. Patients with symptomatic radiographic knee OA who fulfilled ACR classification criteria and had moderate or greater frequent knee pain in one or both knees despite receiving background analgesic and/or anti-inflammatory medicines were randomized to receive either HLXL Dan at a dose of 5,180 mg/day (15 capsules in 3 divided doses) or matching placebo for 8 weeks. Clinical assessments were performed at baseline and weeks 2 and 8 including measurement of knee pain and function with the WOMAC OA Index, patient global assessment (PGA) and PGA of response to therapy (PGART) at end of study. Safety assessments were performed at each visit. Data were analyzed using an intent-to-treat protocol; statistical significance was inferred if P <= 0.05.

Results: A total of 92 patients were enrolled: 53 in the U.S. and 39 in Hong Kong. Overall, the mean age was 60 years, 65 (71%) were women and 64 (70%) were of Asian ethnicity. Mean (SD) baseline WOMAC pain and function score was 4.3 (1.5) and 4.2 (1.6), respectively, and PGA was 2.2 (0.8). There were no significant differences between HLXL- and placebo-treated groups in baseline variables. While both groups had significant improvement in all outcome measures after 8 weeks, there were no significant differences between the HLXL- and placebo-treated groups. At 8 weeks, about two-thirds of subjects noted that they were better based on PGART responses; there was no difference between treatment groups. In mixed models repeated measures analysis, there were no significant differences in WOMAC pain or function scores or PGA between groups; furthermore, there was no interaction between clinical site and degree of improvement. Average adherence exceeded 80 percent and was similar between clinical sites. Finally, there was a significantly greater rise in mean ALT levels in the HLXL-treated group compared with the placebo-treated group (3.8 [10.4] vs 0.1 [5.8] U/l) but no significant difference in either AST or γGT levels.

Conclusion:

These data fail to demonstrate that a proprietary form of the Chinese herbal compound HLXL Dan is efficacious for treating the symptoms of knee OA.


Disclosure:

M. C. Hochberg,

Abbott Laboratories, Astra-Zeneca, Bioiberica S.A., Eli Lilly Inc., Genentech/Roche, Merck Inc., Novartis Pharma A.G., Pfizer Inc., Stryker LLC, Xoma.,

5;

L. Lao,
None;

P. Langenberg,
None;

H. H. S. Fong,
None;

D. Y. W. Lee,
None;

B. Berman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-the-chinese-herbal-compound-hou-lou-xiao-ling-dan-in-patients-with-osteoarthritis-of-the-knee-results-of-a-phase-ii-international-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology